The Alembic Pharmaceuticals Q2 FY27 results, reported for the quarter ended 30 September 2026, show revenue up 36% to about ₹2,603 crore and net profit up 81% to about ₹335 crore. The headline is striking, but the more useful story is the split: US sales rose 77%, the API business 39%, India branded formulations 14% and the rest of the world 12%. This article breaks down each segment, explains the margin gain and flags where reports disagree.
Key takeaways from the Alembic Pharmaceuticals Q2 FY27 results
- Revenue: about ₹2,603 crore, up 36% year on year; first-half FY27 revenue about ₹4,753 crore, up 31%.
- EBITDA: about ₹578 crore, up 78%, with the margin up 520 basis points; by our calculation that is a margin of roughly 22%.
- Net profit: about ₹335 crore, up 81% in one summary of the investor presentation. Other reports give about ₹330 crore and growth between 74% and 94%.
- Segment growth: US up 77%, API up 39%, India branded up 14%, ex-US (rest of world) up 12%.
- R&D was held at about 8% of revenue.
Segment by segment
| Segment | Growth year on year | What we know |
|---|---|---|
| United States | Up 77% | US formulations about ₹1,003 crore in one report, around 38% of revenue by our calculation |
| API | Up 39% | Rupee value not given in the sources |
| India branded | Up 14% | Chronic portfolio cited as a driver |
| Ex-US (rest of world) | Up 12% | Rupee value not given |
The US figure is the engine of the quarter. If US formulations were about ₹1,003 crore, as one report states, the implied prior-year base is roughly ₹567 crore, which is our calculation. That is a rise of about ₹436 crore in a single segment, compared with a total revenue increase of roughly ₹690 crore by our estimate. In other words, the US business accounts for most of the growth.
The US business
Alembic’s management and the summaries we reviewed link the US growth to export volumes and US branded traction, and say operating leverage helped margins. The sources do not break down growth between new product launches, volume gains on existing products and price changes, so we cannot say how repeatable the 77% growth is. US generics markets are known for price competition and for one-off benefits from launches of products with limited competition, but the reports did not say whether such items contributed here.
India, API and the rest of the world
India branded formulations grew 14%, which the summaries tie to the chronic portfolio. API grew 39%, a strong rate for a segment that also supplies the company’s own formulations. The rest of the world grew 12%, the slowest of the four. None of the sources gave rupee values for these segments, so their share of revenue cannot be calculated.
Why margins rose
EBITDA grew 78% against revenue growth of 36%, and the margin rose by about 520 basis points. Gross margin was reported at 73.7%, up 70 basis points, which means most of the margin gain came below the gross line, consistent with operating leverage: sales rose faster than operating costs. R&D stayed at about 8% of revenue, so it did not absorb the extra revenue.
Why profit growth is reported differently
Reports give net profit as about ₹330 crore or ₹335 crore and growth of 74%, 78%, 81% or 94%, depending on the source. The differences may reflect rounding, different comparison bases or one-off items, but the sources do not explain them. We use the figure of 81% from the investor-presentation summary, which fits the prior-year figure of ₹185 crore, and flag the spread. The company’s filing on the BSE website is the authoritative source.
Timeline
- 30 September 2026: end of the quarter.
- Early November 2026: results announced and reported.
- Outlook: summaries project continued growth and return on capital employed of about 15% to 16%, without numerical targets.
Market context: generics and APIs
Acumen Research And Consulting’s Generic Drugs Market report projects the global market at around USD 627.6 billion by 2027, with a compound annual growth rate of about 11.1% for 2020 to 2027, North America holding the major share and Asia-Pacific growing fastest. The page was last updated in April 2021, gives no base-year value and uses 2014 statistics, so we treat it as dated background.
On the API side, Acumen’s Active Pharmaceutical Ingredient Market report, updated in June 2026, puts the market at USD 255.47 billion in 2025 and USD 473.20 billion by 2035, a compound annual growth rate of 6.3% for 2026 to 2035. It gives North America over 39%, Asia-Pacific 25% and Europe about 22% in 2025. Its stated growth rate gives about USD 470 billion by our calculation, a small gap. These are global figures and not Alembic’s.
Our analysis
In our assessment, the quarter is best read as a US-driven step up in profitability rather than broad-based acceleration. India and rest-of-world growth of 14% and 12% are healthy but ordinary. The key question for the coming quarters is whether US growth of 77% reflects a durable portfolio or a strong period that will normalise. The sources do not give enough detail to answer that, and we make no forecast.
What is not disclosed
- Rupee revenue for API, India and ex-US segments in the sources reviewed.
- The split of US growth between volume, price and new launches.
- Any one-off items in the quarter.
- Numerical guidance for revenue or profit.
Risks and caveats
- US generics pricing can change quickly.
- Reports differ on profit and growth rates.
- Market statistics are global, and the generics report is dated.
- This article is news reporting and not investment advice.
What to watch next
- Whether US growth holds in the third quarter.
- Management commentary on product launches and pipeline.
- API demand and pricing.
- Filing details on one-off items.
General background
Company information is at Alembic Pharmaceuticals. Related coverage: the growth of the Indian pharmaceutical market and Emcure Pharmaceuticals’ merger. More in our Pharmaceutical section.
Questions readers are asking about the Alembic Pharmaceuticals Q2 FY27 results
Did Alembic’s profit rise 81%?
One summary of the investor presentation says so; other reports give 74% to 94%, so check the filing.
Which segment grew fastest?
The US, up 77%.
Is the growth broad-based?
Revenue grew in every segment, but the US accounts for most of the increase by our estimate.
FAQ
What is EBITDA?
Earnings before interest, tax, depreciation and amortisation, a measure of operating profit.
What is a basis point?
One hundredth of a percentage point; 520 basis points is 5.2 percentage points.
What does FY27 mean?
The financial year April 2026 to March 2027.
How we reported this: details come from reports of Alembic Pharmaceuticals’ Q2 FY27 results; we did not review the filing. Market figures are attributed to Acumen Research And Consulting. Last updated 4 November 2026. This is news reporting and not investment advice.
